Dicerna Pharmaceuticals Inc. (NASDAQ: DRNA) started the day on October 13, 2021, with a price increase of 2.34% at $21.00. During the day, the stock rose to $21.36 and sunk to $20.62 before settling in for the price of $20.52 at the close. Taking a more long-term approach, DRNA posted a 52-week range of $18.54-$40.14.
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 289.20%. Meanwhile, its Annual Earning per share during the time was 13.20%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 13.70%. This publicly-traded company’s shares outstanding now amounts to $77.03 million, simultaneously with a float of $71.34 million. The organization now has a market capitalization sitting at $1.64 billion. At the time of writing, stock’s 50-day Moving Average stood at $21.58, while the 200-day Moving Average is $27.52.
While finding the extent of efficiency of the company that is accounted for 302 employees. It has generated 544,063 per worker during the last fiscal year. Meanwhile, its income per employee was -373,334. The stock had 1.39 Receivables turnover and 0.25 Total Asset turnover. For the Profitability, stocks operating margin was -68.90 and Pretax Margin of -68.62.
Dicerna Pharmaceuticals Inc. (DRNA) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Dicerna Pharmaceuticals Inc.’s current insider ownership accounts for 0.20%, in contrast to 79.90% institutional ownership. According to the most recent insider trade that took place on Sep 17, this organization’s Chief Scientific Ofr., EVP R&D sold 21,250 shares at the rate of 21.06, making the entire transaction reach 447,516 in total value, affecting insider ownership by 267. Preceding that transaction, on Sep 17, Company’s EVP & Chief Medical Officer sold 2,056 for 21.47, making the whole transaction’s value amount to 44,142. This particular insider is now the holder of 4,969 in total.
Dicerna Pharmaceuticals Inc. (DRNA) Earnings and Revenue Records
In the latest quarterly report released, which was put into the public domain on 6/29/2021, the organization reported -$0.53 earnings per share (EPS) for the three months, lower than the consensus estimate (set at $0.41) by -$0.94. This company achieved a net margin of -68.62 while generating a return on equity of -77.77. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.41 per share during the current fiscal year.
Dicerna Pharmaceuticals Inc.’s EPS increase for this current 12-month fiscal period is 13.70% and is forecasted to reach -1.43 in the upcoming year.
Dicerna Pharmaceuticals Inc. (NASDAQ: DRNA) Trading Performance Indicators
Let’s observe the current performance indicators for Dicerna Pharmaceuticals Inc. (DRNA). It’s Quick Ratio in the last reported quarter now stands at 3.00. The Stock has managed to achieve an average true range (ATR) of 0.86. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 9.16. Similarly, its price to free cash flow for trailing twelve months is now 146.27.
In the same vein, DRNA’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.70, a figure that is expected to reach -0.46 in the next quarter, and analysts are predicting that it will be -1.43 at the market close of one year from today.
Technical Analysis of Dicerna Pharmaceuticals Inc. (DRNA)
If we take a close look at the recent performances of Dicerna Pharmaceuticals Inc. (NASDAQ: DRNA), its last 5-days Average volume was 0.45 million that shows plunge from its year to date volume of 0.85 million. During the previous 9 days, stock’s Stochastic %D was recorded 76.26% While, its Average True Range was 0.82.
Raw Stochastic average of Dicerna Pharmaceuticals Inc. (DRNA) in the period of the previous 100 days is set at 9.20%, which indicates a major fall in contrast to 65.10% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 36.69% that was lower than 73.70% volatility it exhibited in the past 100-days period.